The only scenario where a slightly faster escalation might be considered is for someone transitioning from high-dose tirzepatide (10 to 15 mg) who shows zero GI response at 1 mg and 2 mg
Beginning July 1, 2026, the Medicare GLP-1 Bridge Program may allow eligible Medicare Part D patients to access certain obesity-indicated GLP-1 medications, including Foundayo, Wegovy, and certain Zepbound formulations, for no more than $50 per month through December 31, 2027
Anyone who is 18 years or older (16 or older for acne and birth control prescriptions), and is located in Alberta, British Columbia, Manitoba, Newfoundland and Labrador, Nova Scotia, Prince Edward Island, Saskatchewan or Ontario
However, this is less of an issue for well-known class-specific adverse effects
Fatigue and headache
Theyre simply looking at the scales and saying, Hey, I lost 10 pounds